A5051860370- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Nanoparticle-Based Drug Delivery
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Systemic Sclerosis and Related Diseases
- Biosimilars and Bioanalytical Methods
- Vasculitis and related conditions
- Ocular Diseases and Behçet’s Syndrome
- Immunotherapy and Immune Responses
- Autoimmune and Inflammatory Disorders Research
- Retinal and Optic Conditions
- Cerebral Venous Sinus Thrombosis
- Renal Diseases and Glomerulopathies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Diagnosis and Treatment of Venous Diseases
- Kawasaki Disease and Coronary Complications
- T-cell and B-cell Immunology
- Rheumatoid Arthritis Research and Therapies
- Autoimmune Bullous Skin Diseases
- Adenosine and Purinergic Signaling
- Otitis Media and Relapsing Polychondritis
University of Pisa
2013-2024
Ospedale Santa Chiara
2016
Center for Rheumatology
2013
AB598 is a CD39 inhibitory antibody being pursued for the treatment of solid tumors in combination with chemotherapy and immunotherapy. metabolizes extracellular adenosine triphosphate (eATP), an alarmin capable promoting antitumor immune responses, into adenosine, immuno-inhibitory metabolite. By inhibiting CD39, consumption eATP reduced, resulting proinflammatory milieu which can activate myeloid cells to promote immunity. The preclinical characterization provides mechanistic rationale...
T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8+ tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against TIGIT, it necessary understand IgG Fc (Fcγ) binding...
Objectives: Vascular involvement is a key feature of systemic sclerosis (SSc). changes are central to the pathogenesis disease and assessment vascular has prognostic value. This therefore pivotal role in management SSc patients. The aim our study was evaluate post-occlusive reactive hyperaemia (PORH) consecutive patients test whether PORH might be useful tool for early diagnosis SSc.Method: Between April 2011 2015, 60 (mean age 56 ± 15 years, females:males = 18:1) were enrolled study....
<h3>Background:</h3> Anifrolumab (ANI) is a fully human monoclonal antibody against the type I interferon receptor that has recently been approved for treatment of moderate to severe Systemic Lupus Erythematosus (SLE) as an add-on standard care. Data from randomized controlled trials have demonstrated its efficacy and safety, but real-world data are still limited, especially regarding impact this new drug on patients' quality life (QoL). <h3>Objectives:</h3> To evaluate effect ANI therapy...
<p>Figure S1</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S9</p>
<p>Supplemental Tables 1–3</p>
<p>Figure S10</p>
<p>Figure S9</p>
<p>Figure S8</p>
<p>Figure S10</p>
<p>Figure S1</p>
<p>Supplemental Tables 1–3</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S8</p>
<p>Figure S5</p>
<p>Figure S7</p>
<p>Figure S4</p>
<p>Figure S5</p>
<p>Figure S6</p>
<p>Figure S2</p>
<p>Figure S3</p>